Chemistry: analytical and immunological testing – Cancer
Reexamination Certificate
1999-11-24
2002-09-17
Warden, Jill (Department: 1743)
Chemistry: analytical and immunological testing
Cancer
C436S813000
Reexamination Certificate
active
06451609
ABSTRACT:
BACKGROUND OF THE INVENTION
Gynecological carcinomas such as ovarian carcinoma, cervical carcinoma, endometrial carcinoma and peritoneal carcinoma are among the most frequent causes of cancer death among women in the United States and Europe. It is estimated that ovarian carcinoma alone will be responsible for 14,800 deaths in 1996 in the United States. This dismal outcome is due, at least in part, to an inability to detect the ovarian carcinoma at an early stage of tumor development. When ovarian carcinoma is diagnosed at an early stage, the cure rate approaches 90%. In contrast, the 5 year outlook for women with advanced disease remains poor with no more than a 15% survival rate. Thus, early diagnosis is one of the most effective means of improving the prognosis for ovarian carcinoma.
Transvaginal sonography is the most sensitive of the currently available techniques used for detecting ovarian tumors. However, transvaginal sonography is non-specific, i.e. it will detect benign as well as malignant tumors. Accordingly, detection of an ovarian tumor by transvaginal sonography must be followed by a second diagnostic procedure which is able to distinguish benign tumors from malignant tumors. Moreover, transvaginal sonography is very expensive and, therefore, not useful as a screening procedure for large numbers of patients.
Typically, benign ovarian tumors are distinguished from malignant ovarian tumors by surgical procedures such as biopsy of the mass or aspiration of the mass and cytological examination of the cells that are surgically removed from the patient. However, these techniques are highly invasive, expensive, and in the case of aspiration can lead to release of cancerous cells into the peritoneum.
The antigenic determinant CA 125, which is a high molecular weight mucin-like glycoprotein, is the current serum biomarker of choice for screening for ovarian carcinomas. However, CA 125 testing suffers from two main limitations. First of all, it is not very sensitive. For example, elevated serum CA 125 levels, i.e. levels above the cut-off point of 35 U/ml, are present in fewer than 50% of the patients with Stage I ovarian carcinoma. Taylor, K. J. W. and Schwartz, P. E., “Screening for Early Ovarian Cancer,” Radiology, 192:1-10, 1994. In addition, CA 125 testing is not very specific. For example, approximately 25% of patients. with benign gynecological diseases also have elevated serum levels of CA 125. Moreover, liver disease such as cirrhosis, even without ascites, elevates serum CA 125 levels above 35 U/ml. Taylor, K. J. W. and Schwartz, P. E., “Screening for Early Ovarian Cancer,” Radiology, 192:1-10, 1994.
Accordingly, it would be desirable to have a new, simple, noninvasive or marginally invasive methods for detecting gynecological carcinomas, particularly ovarian carcinomas. Methods which are sufficiently sensitive to identify those subjects with early stage ovarian carcinoma, and sufficiently specific to distinguish between benign and malignant gynecological carcinomas are especially desirable.
SUMMARY OF THE INVENTION
The present invention provides new, simple, marginally-invasive methods for detecting the presence of gynecological carcinomas, particularly ovarian carcinomas, in a subject.
One method comprises assaying for the presence of lysophosphatidic acid in a plasma sample. The presence of lysophosphatidic acid in the plasma sample indicates that a gynecological carcinoma is present in the subject. In a preferred embodiment, the method comprises preparing a plasma sample which is substantially free of platelets from a blood specimen from the subject, preparing a lipid extract from said plasma sample, and assaying for the presence of lysophosphatidic acid in said lipid extract. Because the method is sufficiently sensitive to detect ovarian carcinoma in subjects with early stage ovarian carcinoma, sufficiently specific to distinguish benign gynecological carcinomas from malignant gynecological carcinomas, and marginally invasive, the method is especially useful for screening patients for ovarian carcinomas. The method also detects the presence of endometrial carcinoma, peritoneal carcinoma, and cervical carcinoma in a subject. Accordingly, the method is useful for screening for more than one gynecological carcinoma.
Another method comprises assaying for the presence of lysophophatidyl inositol in a bodily fluid, preferably a blood sample from the subject. Preferably, the concentration of the lysophosphatidyl inositol in the bodily fluid is determined.
REFERENCES:
patent: 4999344 (1991-03-01), Jett-Tilton et al.
patent: 5277917 (1994-01-01), Xu et al.
patent: 5326690 (1994-07-01), Xu et al.
patent: 5595738 (1997-01-01), Pomato et al.
patent: 5824555 (1998-10-01), Xu et al.
patent: 5994141 (1999-11-01), Xu et al.
patent: WO 98/43093 (1998-10-01), None
Translation of abstract of article by Misako Okita,Bulletin of the department of health and welfare, Okayama Prefectural University, vol. 1-1, pp. 29-35, 1994.
“Effect of Lysophospholipids on Signaling in the Human Jurkat T Cell Line” by Xu, et al.,Journal of Cellula Physiology, 163:441-450 (1995).
“Lysophospholipids activate ovarian and breast cancer cells” by Xu, et al.,Biochem. J.,(1995) 309, 933-940.
“Characterization of an Ovarian Cancer Activating Factor in Ascites from Ovarian Cancer Patients” by Xu, et al.Clinical Cancer Research, vol. 1, pp. 1223-1232, Oct. 1995.
“Growth factor-like effects of lysophosphatidic acid, a novel lipid mediator” by Jalink, et al.,Biochemica et Biophysica Acta, 1198 (1994) 185-196.
“Lysophosphatidic Acid, a Multifunctional Phospholipid Messenger” by Mooleanaar,The Journal of Biological Chemistry, vol. 270, No. 2, pp. 12949-12952, Jun. 2, 1995.
“Lysophosphatidic acid possesses dual action in cell proliferation” by Tigyi, et al.,Proc. Natl. Acad. Sci. USA, vol. 91, pp. 1908-1912, Mar. 1994.
“Decanoyl lysophosphatidic acid induces platelet aggregation through an extracellular action” by Watson, et al.,Biochem. J.,(1985) 232, pp. 61-66.
“LPA: a novel lipid mediator with diverse biological actions” by Moolenaar,Trends in Cell Biology, vol. 4, pp. 213-218, Jun. 1994.
“Increased phosphatidic acid and decreased lysophosphatidic acid in response to thrombin is associated with inhibition of platelet aggregation” by Gerrard, et al.,Biochem. Cell Biol.,vol. 71, pp. 432-439, 1993.
“Lysophosphatidic Acid as a Potential Biomarker for Ovarian Cancer and Other Gynecological Cancers” by Xu, et al.,The Journal of the American Medical Association,vol. 280, No. 8, pp. 719-723, Aug. 26, 1998.
“Peptide and Lipid Growth Factors Decrease cis-Diamminedichloroplatinum-induced Cell Death in Human Ovarian Cancer Cells” by Frankel, et al.,Clinical Cancer Research, vol. 2, pp. 1307-1313, Aug. 1996.
“Role of Growth Factors: Their Receptors and Signalling Pathways in the Diagnosis, Prognosis, Follow-Up and Therapy of Ovarian Cancer” by Mills, et al.,Diagn Oncol, 1992;2:39-54.
“Phorbol 12-Myristate 13-Acetate Simulates Lysophosphatidic Acid Secretion from Ovarian and Cervical Cance Cells but Not from Breast or Leukemia Cells” by Shen, et al.,Gynecologic Oncology, 71, 364-368 (1998).
“Elevated Levels and Altered Fatty Acid Composition of Plasma Lysophosphatidylcholine(LYSOPC) in Ovarian Cancer Patients” by Okita, et al.,Int. J. Cancer,71, 31-34 (1997).
“Activation of human ovarian cancer cells: role of lipid factors in ascitic fluid” by Xu, et al, Chapman & Hall Medical, London, Glasgow, Weinheim, New York, Tokyo, Melbourne, Madras, pp. 121-135 (1994).
“Malignant effusions contain lysophosphatidic acid (LPA)-like activity” by Westermann, et al.,Annals of Oncology, 9, pp. 437-442 (1998).
“Soluble Interleukin-2 Receptor Alpha is Elevated in Sera of Patients with Benign Ovarian Neoplasms and Epithelial Ovarian Cancer” by Hurteau, et al,Cancer, vol. 76, No. 9, pp. 1615-1620, Nov. 1, 1995.
“A Putative New Growth Factor in Ascitic Fluid from Ovarian Cancer Patients: Identification, Characterization, and Mechanisms of Action” by Mills, et al.,Cancer Research, 48, 1066-1071, Mar. 1, 1988.
“Ascitic Fluid from Human Ovari
Xiao Yijin
Xu Yan
Calfee Halter & Griswold LLP
Cole Monique T.
The Cleveland Clinic Foundation
Warden Jill
LandOfFree
Method of detecting gynecological carcinomas does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of detecting gynecological carcinomas, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of detecting gynecological carcinomas will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2853538